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Osteoporosis as a Community Health Problem: Lessons Learned From
Studying Hypertension
Michael Kleerekoper, MD,* and Dorothy A. Nelson, PhD*

Campaigns to increase the medical and lay communities' awareness and understanding ofthe
problems of unrecognized and untreated hypertension have led to a progressive decline in morbidity
and mortalily from hypertension-related diseases. While osteoporosis is also a community health
problem, educational and awareness campaigns are still in their infancy and decades may pass before
these resuh in a declining morbidity and mortalily from osteoporosis. We identify areas where
concepts learned from years of hyperiension research mighl be appUcable lo the study of osteoporosis as a community health problem and thereby lessen the time needed to effect a declining morbidity
and mortality from osteoporosis. We discuss the importance ofa more specific diagnostic classification and the implications of these concepts for clinical trial design. (Henry Ford Hosp Med J 1988;
36:113-6)

A

major triumph in community medicine during the past several decades has been the campaign to increase public
awareness of the dangers of unrecognized and untreated hypertension—the so-called "silent epidemic." Recent health
care statistics show a progressive decline in the death rate from
myocardial infarction and stroke (1).
Osteoporosis is a community health problem of lesser magnitude than hypertension and its sequelae but is nonetheless
of significant proporfions. Available data on the incidence and
prevalence of osteoporosis indicate that even by a most conservative estimate 5% to 10% of all white women in the United
States will have sustained at least one osteoporotic vertebral
compression fracture by age 70 (2,3) and that the health care
cost of osteoporotic fractures exceeded $6 billion in 1986 (4).
Increasing physician and public awareness of osteoporosis is
a phenomenon of the 1980s that parallels the public awareness
campaign for hypertension. We will explore some of the similarities between these two disorders to determine whether any
ofthe lessons leamed from decades of hypertension community
action programs can guide us in our approach to the problem of
osteoporosis. In particular, we discuss the importance of more
specific diagnostic criteria, implications for prevenfion and therapy, and suggestions for effective clinical trial design.

artery using a standard, calibrated sphygmomanometer. When
BP is measured at a different site or by a different technique, a
modifying comment is always appended.
No convenfion yet exists concerning the site and method
of measuring bone mineral density (BMD). Even a preferred
nomenclature does not exist, with terms such as bone mass,
bone density, bone mineral content, and bone mineral density
used interchangeably despite subfie but important differences in
their meaning.
As BP has systolic and diastolic components, BMD has cortical and trabecular components. While these components of B P
or BMD are related in apparently healthy subjects, this is not
necessarily true, and information about one often cannot be
inferred from knowledge of the other. Similarly, disease states
exist in which the measurement of one component of BP or
BMD is normal and the other is abnormal. Both systolic and diastolic BP are measured at the same site using the same methodology, but this is not yet possible for B M D measurements
with current technology and may never be possible. With the
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By convenfion the term blood pressure (BP) implies measurement of systolic and diastolic blood pressure in the brachial
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exception of quantitative computed tomography which specifically selects a region of interest prior to measurement, current
methods of BMD measurement cannot distinguish between cortical and trabecular bone.

Abnormal Measurement
Both BP and BMD change normally with normal aging,
albeit in opposite directions. This age-related change in
normal values is not necessarily trivial since those diseases
resulting from prolonged abnormalities in BP or BMD become
increasingly more prevalent with advancing age. Nonetheless,
before assigning a disease process to an apparent abnormality
detected in a measurement it is essential that the correct reference interval be employed. One important difference between
the reference intervals for BP and BMD, in addition to being
age-dependent, is that the reference interval for BMD is also
gender- and race-related, with normal males having a higher
BMD than normal females and normal blacks having a higher
BMD than normal whites (5,6).
When the measured BP is above the appropriate reference interval, the subject in whom the measurement was made is given
the diagnostic label "hypertension." In most cases hypertension
is asymptomatic and in the strictest sense of the word is not
really a disease until complicated by a morbid event such as a
stroke or myocardial infarction. However, the simple act of
attaching the disease label "hypertension" to an asymptomatic
person increases absenteeism from the workplace by as much as
80% (7-9) even though the reason for the absenteeism is seemingly unrelated to the elevated BP.
When the measured BMD is below the reference interval,
most physicians append the diagnostic label "osteoporosis,"
making no distinction between this asymptomatic condition and
the clinical disease in which the low BMD is complicated by
nontraumatic fractures. Unfortunately, no suitable skeletal
equivalent of "hypertension" exists, ie, a descriptor of the condition of having a low BMD. "Osteopenia" is gaining some acceptance in this regard, but it is unlikely that widespread use
of this term will penetrate most of the medical or lay communities. The rapid deployment of "osteoporosis screening centers" throughout the United States (4,10-12) all but ensures the
continued use of the term osteoporosis to include both the
asymptomatic subject with an abnormal measurement and
the patient who is terminally ill from complications of an
osteoporotic proximal femur fracture.
Despite the limitations of current terminology, it is essential
that we leam from the experience with the diagnosis of hypertension as a cause of morbidity and absenteeism and not perpetuate this error in the case of a low BMD. As more women
enter and remain in the work force past the age where a low
BMD becomes more prevalent, this situation might worsen if
patients with mechanical lower back pain and a subnormal BMD
were labeled as having "osteoporosis" even though fractures
had not yet occurred. It is therefore imperative to develop either
an acceptable skeletal equivalent to the term hypertension or
the routine use of modifiers to distinguish the asymptomatic
premorbid "osteoporosis without fractures" from the morbid
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condition of "osteoporosis with fractures (spine, hip, forearm, etc)."

Preventing an Elevated BP or Low BMD
Although the precise etiology of essential hypertension is unknown, several diet and life-style factors appear to be important
in maintaining a normal BP. Epidemiologic studies suggest, at
least in susceptible individuals and animal models, that a high
sodium intake predisposes to hypertension (13). Similar observations have been made recently in people and experimental
animals conceming a low dietary calcium intake and the development of hypertension (14,15). Further studies are needed to
identify, if possible, persons with a susceptibility to develop an
elevated BP if exposed during their formative years to a diet that
is too high in sodium, too low in calcium, etc. Similar comments could be made conceming obesity and the development of
hypertension. A major factor in the pathogenesis of hypertension, genetic predisposition, is not yet susceptible to change.
Much more is known about the pathogenesis of the most common form of osteoporosis, postmenopausal osteoporosis, than
about the pathogenesis of essential hypertension. From a community health point of view, the problem of osteoporosis is
largely confined to white females. (While hypertension is more
prevalent in blacks than in whites, the prevalence in each ofthese
subgroups is sufficiently great to render hypertension a community health problem for both sexes and races.) The reason for the
greater prevalence of osteoporosis in this white female population later in life is already apparent by age 25 or 30 when peak
adult BMD is achieved (16,17). By this age males already demonstrate a higher BMD than females, and blacks have a higher
BMD than whites at all ages (16). By optimizing their dietary
calcium intake during childhood and adolescence and maintaining an optimum program of load-bearing physical activity during the same period, young women can optimize peak adult
BMD and minimize the risk of subsequent osteoporosis (18).
Little is known about factors that govem BMD between age 25
and the menopause, but some of the pieces of the puzzle are beginning to fall into place. Nulliparity is associated with a greater
likelihood of osteoporosis in later life (19,20), as is a pattern of
irregular menses during the reproductive years. Conversely,
multiparity and use of oral contraceptives appear to provide
some advantage with respect to maintaining an optimum BMD
(19,21). The single most important factor in maintaining a normal BMD throughout life for most women is the avoidance of
hypogonadism. Practically, this means adequate hormonal replacement therapy at the time of the menopause, a program that
has been conclusively shown to retard postmenopausal bone
loss and to reduce the likelihood of osteoporotic fractures
(2,22). As is the case with hypertension, any genetic predisposition toward osteoporosis is not amenable to change.

Treating Acute Complications
No curative therapy exists for an acute hypertensive cerebrovascular accident (hemorrhagic stroke) but much can and
should be done to minimize the affected area ofthe brain. This
therapy includes cautious lowering of the BP if elevated at the
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time ofthe stroke, although many of the more potent antihypertensive agents are relatively contraindicated in patients with a
completed stroke. Once the patient is stable after the cerebrovascular accident, the mainstay of therapy is rehabilitation to
restore and maintain an optimal functional state. Rehabilitation
is also the mainstay of therapy following an acute myocardial
infarction that complicates chronic uncontrolled hypertension,
although recent advances in angioplasty and thrombolytic therapy offer a more aggressive and potentially more rewarding
approach to therapy.
The only recognized complication of a chronically low BMD
is a fracture that occurs in the absence of trauma or in response to
only trivial trauma. Although therapy is dependent on the site of
fracture, rehabilitation also plays a major role. The distal forearm (Colles) osteoporotic fracture is a relafively trivial event
treated with closed reduction for a short fime followed by physical therapy until the expected full restoration of prefracture
function. With the proximal femur (hip) osteoporotic fracture,
open reduction followed by early ambulation and an aggressive
physical therapy/rehabilitation program is the treatment of
choice. When the patient is too frail to undergo surgery, the rehabilitation program is also limited and the prognosis is poon
Overall, despite significant improvements in surgical techniques and physical therapy, there is still a 20% mortality during
thefirstthree months following an osteoporotic hip fracture, and
at the end of one year only one third of the patients are restored to
their prefracture functional state (23,24). For the mo.st common
osteoporotic fracture, vertebral compression fractures, no surgical approach is possible and the treatment program must revolve around an active rehabilitation program. With the possible
exception of the Colles fracture that occurs most frequently in
thefirstdecade after the menopause, estrogen has a very limited
documented role in the management ofthe patient with fractures
complicating a low BMD.
This is not meant to imply that attempts should not be made to
lower the BP in patients who have had a stroke or a heart attack
or to increase the BMD in patients who have sustained an
osteoporotic fracture. However, often this approach is too little
too late; drugs and changes in life-style that are of critical importance in preventing the end-organ damage have a lesser role
once that complication has occurred, and rehabilitation becomes
crucial to the maximum recovery and maintenance of function
following a stroke or an osteoporotic fracture.

Lessons to be Learned
In one important respect, osteoporosis has much to teach
hypertension. The segment of society at greatest risk for developing osteoporosis (postmenopausal white females) is clearly
identifiable. Furthermore, we already know how to prevent the
premorbid asymptomatic state of having a low BMD (adequate
dietary calcium and physical activity during the developing
years and adequate gonadal hormone replacement in the immediate postmenopausal years). For many individuals an elevated
BP can be avoided by careful attention to dietary sodium intake
and avoidance of obesity, but it is not yet possible to identify
those people who will benefit from this, nor is it known at what
age this prophylactic program should begin.
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Many more lessons that have already been leamed from the
hypertension/stroke aspect should now be applied to the osteopenia/osteoporosis field. Most importantiy, it is time to focus
attention with respect to drug therapy on those patients who have
already been identified as having a low BMD (analogous to the
treatment of patients with a high BP). Numerous clinical trials
are currently under way to determine if a particular drug regimen
can significantiy reduce the fracture rate in patients who already
have one or more fractures as an entry criterion for the trial. We
believe that it is even more important to do trials in which the
entry criterion is a reduction in BMD and the criterion for success is an increase or stabilization in BMD. Classes of dmgs capable of increasing BMD should be developed and subjected to
vigorous clinical trials. Many classes of antihypertensive medications have been developed and successfully introduced into
clinical medicine even though the precise pathogenesis of essential hypertension remains enigmafic. Occasionally the pharmacologic action created by these dmgs is only fully elucidated
by studies completed after antihypertensive efficacy has been
demonstrated. Therefore, there is no inherent need to await the
complete unravelling of the pathogenesis of bone loss before
newer drugs aimed at increasing BMD are developed and investigated. Pafients entered into these trials ideally should be
followed long enough to permit quantitafion of morbidity endpoints (fractures), but this should not be the primary end-point of
such trials.
No single dmg therapy for hypertension exists, and even in
the individual pafient more than one drug is often required. Of
the several different etiologies for hypertension that have been
postulated over the years, many of these theories have been successfully translated into new BP-lowering drugs or classes of
drugs. The generafion of new information about the biology of
bone and the mechanisms of bone loss and bone formation
should also result in newer drug therapies. To a certain extent
this is starting to happen as is the case with the ADFR (activatedepress-free-repeat) approach (25) to the treatment of osteoporosis. In the long term this particular theory may prove to
be incorrect or incomplete, but for now it is clearly a step in the
right direction.
We all must acknowledge for practical purposes of investigating and understanding osteoporosis that it is a recentiy recognized disorder being studied with very new technology. We
must learn the capabilities and limitations of each new advance
and avoid the temptation to expect all the answers to come tumbling out with every new piece of the puzzle as it unfolds. We
must increase public awareness about osteoporosis yet be careful to avoid inducing unnecessary fear in healthy people or false
optimism in those already afflicted. This can happen only if the
medical community remains precise in our use of bone mass
measuring techniques and particularly in the terminology with
which aspects of this disease are discussed among ourselves and
with our patients. The reasoned approach to hypertension is just
now beginning to pay off for the community. With time the same
will be true for osteoporosis.
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